Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / KPTI - Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

KPTI - Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Karyopharm Therapeutics Inc.

2024-02-05 12:26:46 ET

Summary

  • Karyopharm Inc. has entered the realm of undervalued biotech stocks, making it a potential buying opportunity.
  • The company's main drug, selinexor, is currently approved for the management of multiple myeloma and diffuse large B-cell lymphoma.
  • Karyopharm is pursuing indications for myelofibrosis and endometrial cancer, with promising preliminary data and ongoing clinical trials.
  • Substantial risks remain, and their most important catalysts are still far off, but it's hard to ignore the potential discount of this company.

Topline Summary and Update

For further details see:

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)
Stock Information
Company Name: Karyopharm Therapeutics Inc.
Stock Symbol: KPTI
Market: NASDAQ
Website: karyopharm.com
Menu
KPTI KPTI Quote KPTI Short KPTI News KPTI Articles KPTI Message Board
Get KPTI Alerts

News, Short Squeeze, Breakout and More Instantly...